Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 9/20 | 0.50 |
| ▸ | AVPR1B | P47901 | 6/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2499319 | 0.91 | ADAM17 (0.50) | ADAMTS5AVPR1BADAM17MMP13MMP2 | |
| SCHEMBL2494093 | 0.88 | ADAM17 (0.44) | ADAMTS5AVPR1BADAM17MMP13MMP2 | |
| SCHEMBL2493671 | 0.87 | KDM4E (0.49) | ADAMTS5ADAM17MMP13MMP2MEN1 | |
| SCHEMBL2492716 | 0.86 | AVPR1B (0.49) | ADAMTS5AVPR1BADAM17MMP13MMP2 | |
| SCHEMBL2498584 | 0.86 | ADAM17 (0.45) | ADAMTS5ADAM17MMP13MMP2MEN1 | |
| SCHEMBL2496303 | 0.85 | KDM4E (0.54) | ADAMTS5ADAM17MMP13MMP2MEN1 | |
| SCHEMBL2499269 | 0.83 | ADAM17 (0.44) | ADAMTS5ADAM17MMP13MMP2MEN1 | |
| SCHEMBL5674476 | 0.83 | HTR7 (0.45) | ADAMTS5ADAM17MMP13MMP2TSHR | |
| SCHEMBL5675399 | 0.82 | ADAMTS5 (0.41) | ADAMTS5ADAM17MMP13MMP2MEN1 | |
| SCHEMBL2492641 | 0.82 | TP53 (0.44) | ADAMTS5ADAM17MMP13MMP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | ADAMTS5 1111/4885AVPR1B 1/4885ADAM17 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.